NCT06951464View on ClinicalTrials.gov

A Study of BL-B01D1 and Almonertinib in Patients With Resectable EGFR+ Stage II-IIIB NSCLC

PHASE2RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

June 25, 2025

Primary Completion Date

May 5, 2027

Study Completion Date

March 5, 2029

Conditions
Non-Small Cell Lung Cancer
Interventions
DRUG

BL-B01D1

BL-B01D1 (2.2 or 2.5mg/kg) to be administered on Day 1 and Day 8 of every 3-week cycle for 2 cycles.

DRUG

Almonertinib

Almonertinib 100mg QD

Trial Locations (1)

610041

RECRUITING

West China Hospital, Sichuan University, Chengdu

All Listed Sponsors
lead

Sichuan University

OTHER

NCT06951464 - A Study of BL-B01D1 and Almonertinib in Patients With Resectable EGFR+ Stage II-IIIB NSCLC | Biotech Hunter | Biotech Hunter